Boston TechBio Startup Raises $45M Series A for Autonomous Wet-Lab Protein Screening

Closing the Biological Feedback Loop

The greatest bottleneck in generative AI for medicine hasn't been model architecture—it has been physical wet-lab verification. Algorithms can generate millions of theoretical molecular structures, but testing whether they actually bind to disease targets takes months.BioSynth Labs, based in Kendall Square, Cambridge, has raised $45M in Series A funding led by premier biotech check-writers ARCH Venture Partners and Flagship Pioneering to solve the verification bottleneck.

Physical Autonomous Wet Labs

BioSynth pairs computational biology models with physical robotic liquid-handling workcells. When the AI designs novel antibody candidates, robotic arms immediately synthesize the proteins and execute binding assays. The real-world assay results are fed back into the foundation model within 4 hours, creating an exponential closed-loop discovery cycle.

What Life Sciences Investors Look For

Biotech VCs have grown skeptical of pure 'in-silico' software companies that lack wet-lab validation. In 2026, premium Series A valuations require proprietary physical generation infrastructure and verified preclinical data.